| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/04/2002 | WO2002026212A2 Microparticle compositions and methods for the manufacture thereof |
| 04/04/2002 | WO2002026211A1 Topical polymeric antimicrobial emulsion |
| 04/04/2002 | WO2002026209A2 Microparticles for delivery of the heterologous nucleic acids |
| 04/04/2002 | WO2002026208A2 Emulsion vehicle for poorly soluble drugs |
| 04/04/2002 | WO2002026191A2 Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| 04/04/2002 | WO2002008435A8 Codon-optimized papilloma virus sequences |
| 04/04/2002 | WO2002004012A8 Anhydrous pharmaceutical composition of vancomycin for topical use |
| 04/04/2002 | WO2002003961B1 Microspheres and adjuvants for dna vaccine delivery |
| 04/04/2002 | WO2002002084A8 Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| 04/04/2002 | WO2002000167A3 Modified forms of pharmacologically active agents and uses therefor |
| 04/04/2002 | WO2001098327A3 Glycopeptide carboxy-saccharide derivatives |
| 04/04/2002 | WO2001098326A3 Glycopeptide disulfide and thioester derivatives |
| 04/04/2002 | WO2001097837A8 Solubilised protein vaccines |
| 04/04/2002 | WO2001097795A3 Systems and methods for treating a mucosal surface |
| 04/04/2002 | WO2001097678A3 Imaging and targeting tumors using sickle cells |
| 04/04/2002 | WO2001096450A3 Fast cure film forming formulation |
| 04/04/2002 | WO2001089577A3 Conjugates of aminodrugs comprising an oxime bond |
| 04/04/2002 | WO2001089449A3 Phospholipase d effectors for therapy and screening |
| 04/04/2002 | WO2001087376A8 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 04/04/2002 | WO2001087263A3 Delivery systems for treatment of vascular disease |
| 04/04/2002 | WO2001085184A3 Nontoxic vernix compositions and method of producing |
| 04/04/2002 | WO2001085142A8 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| 04/04/2002 | WO2001082954A3 Ceruloplasmin and uses thereof in neurodegenerative related conditions |
| 04/04/2002 | WO2001072846A3 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 04/04/2002 | WO2001068102A3 Nystatin formulation having reduced toxicity |
| 04/04/2002 | WO2001053354A3 Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules |
| 04/04/2002 | WO2001048231A3 Method of achieving persistent transgene expression |
| 04/04/2002 | WO2001034182A3 Composition for treating respiratory tract infections containing menthol, eucalyptol and an alpha-amylase |
| 04/04/2002 | WO2001032219A3 Treatment of c. difficile toxin b associated conditions |
| 04/04/2002 | WO2001030390A3 Method |
| 04/04/2002 | WO2001012232A3 Process to make a sustained release formulation |
| 04/04/2002 | US20020040203 Method for transdermal or intradermal delivery of molecules |
| 04/04/2002 | US20020040128 Carbohydrate-blood protein complex for us as an oxygen transporter |
| 04/04/2002 | US20020040076 Poly(ethylene glycol) derivatives with proximal reactive groups |
| 04/04/2002 | US20020040064 Administering agent that inhibits the contraction or migration of smooth muscle cells; sustained dosage; biological stents |
| 04/04/2002 | US20020040063 Liquid formulation of metformin |
| 04/04/2002 | US20020040061 Compounds such as 1-(3-(2-hydroxybenzoylamino)propyl)-2-pyrrolidinone; dosage forms of bioactive agents or drugs |
| 04/04/2002 | US20020040051 Solid dispersion of ipriflavone for oral administration and its manufacturing methods |
| 04/04/2002 | US20020040015 Administering to the mammal an anti-angiogenesis factor and a photosensitizer to permit to localize in the chorodial neovasculature, irradiating the chorodial neovasculature with laser light |
| 04/04/2002 | US20020040004 Administering to mammal a mixture of proteins derived from ground bone to provide increased blood flow to tissue served by an occluded or partly occluded vessel |
| 04/04/2002 | US20020039999 Antinociceptive agent derivative |
| 04/04/2002 | US20020039996 Pharmaceutical administration form for peptides, process for its preparation, and use |
| 04/04/2002 | US20020039994 Administering anticoagulant agent |
| 04/04/2002 | US20020039957 Glass ionomer-based fluoride applying material |
| 04/04/2002 | US20020039774 Anticholesterol agents |
| 04/04/2002 | US20020039601 Cancer cell growth suppressor and cell differentiation inducer and method for manufacturing the same |
| 04/04/2002 | US20020039598 Stabilized pharmaceutical composition and its production |
| 04/04/2002 | US20020039594 Solid porous matrices and methods of making and using the same |
| 04/04/2002 | US20020039592 Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| 04/04/2002 | US20020039590 Nontoxic vernix compositions and method of producing |
| 04/04/2002 | US20020039581 Antibodies against CTLA4 and uses therefor |
| 04/04/2002 | US20020039573 Administering antigen; genetic engineering |
| 04/04/2002 | US20020039560 Drug delivery |
| 04/04/2002 | DE10045591A1 Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) Site-specific, antibody-mediated activation of proapoptotic cytokines - Amaize (Antibody Mediated Apoptosis Inducing cytokines) |
| 04/04/2002 | DE10044846A1 Mittel mit verlängerter Magenverweilzeit zur Erzeugung eines langanhaltenden Sättigungseffektes sowie dessen Verwendung Agent with a prolonged gastric residence to produce a long-lasting satiation effect and its use |
| 04/04/2002 | CA2426666A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | CA2423991A1 Pumpcn compositions and uses thereof |
| 04/04/2002 | CA2423492A1 A fibrin/fibrinogen-binding conjugate |
| 04/04/2002 | CA2423487A1 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 04/04/2002 | CA2423484A1 Instant water dissolvable encapsulate and process |
| 04/04/2002 | CA2423483A1 Taxoid conjugates as antimitotic and antitumor agents |
| 04/04/2002 | CA2423201A1 Stabilized hydrogen peroxide solutions |
| 04/04/2002 | CA2422916A1 Compounds and methods for use thereof in the treatment of cancer or viral infections |
| 04/04/2002 | CA2420672A1 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 04/03/2002 | EP1192946A1 Use of mometasone furoate for treating airway passage and lung diseases |
| 04/03/2002 | EP1192942A2 Base material for dry direct tableting comprising low-substituted hydroxypropyl cellulose |
| 04/03/2002 | EP1192938A2 Composition to enhance permeation of topical skin agents |
| 04/03/2002 | EP1192934A2 Emulsion preparations of the w/o type with an increased water content based on lipidic components |
| 04/03/2002 | EP1192253A1 Icbp90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer |
| 04/03/2002 | EP1192228A1 A color containing silica resistant to dye migration and method of making the same |
| 04/03/2002 | EP1192147A1 Mycolactone and related compounds, compositions and methods of use |
| 04/03/2002 | EP1192134A2 Processes for the preparation of (r)-g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol |
| 04/03/2002 | EP1191999A1 Method of particle formation |
| 04/03/2002 | EP1191947A1 Methods for treating avm' using radioactive compositions |
| 04/03/2002 | EP1191944A2 METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
| 04/03/2002 | EP1191943A1 Novel anti-allergic agents |
| 04/03/2002 | EP1191933A1 Nasal delivery of apomorphine |
| 04/03/2002 | EP1191927A1 Microreservoir system on the basis of polysiloxanes and ambiphilic solvents |
| 04/03/2002 | EP1191926A1 New formulation |
| 04/03/2002 | EP1191925A2 Sustained release dosage form unit having latex coating and method of making the same |
| 04/03/2002 | EP1191924A1 Pharmaceutical dosage form for pulsatile delivery of (d-threo)-methylphenidate and a second cns stimulant |
| 04/03/2002 | EP1191923A1 Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions |
| 04/03/2002 | EP1191843A2 Antibacterial compositions |
| 04/03/2002 | EP1174124A9 Percutaneous administration preparations |
| 04/03/2002 | EP1133319A4 Photosensitizer conjugates for targeting intracellular pathogens |
| 04/03/2002 | EP0999838B1 Self-emulsifying formulation for lipophilic compounds |
| 04/03/2002 | EP0924996B1 Use of bilayer forming emulsifiers in nutritional compositions comprising divalent metal salts |
| 04/03/2002 | EP0918507B1 Aerosol formulations |
| 04/03/2002 | EP0907356B1 Aerodynamically light particles for pulmonary drug delivery |
| 04/03/2002 | EP0853476B1 Pharmaceutical preparation containing nimesulide for topical use |
| 04/03/2002 | EP0809512B1 Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin |
| 04/03/2002 | EP0767663B1 Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide |
| 04/03/2002 | EP0739199B1 Estradiol penetration intensifier for transdermal administration |
| 04/03/2002 | EP0736002B1 Compound capable of introducing at least one molecule into a cell |
| 04/03/2002 | EP0728155B1 Water soluble active sulfones of poly(ethylene glycol) |
| 04/03/2002 | EP0676962B9 Enhanced pharmaceutical compositions for skin penetration for piroxicam |
| 04/03/2002 | EP0667163B1 Powder for nasal administration of peptidic or proteinaceous drug |
| 04/03/2002 | CN1343205A Dimeric compounds and as inhibitors of neuraminidase |
| 04/03/2002 | CN1343174A 计量阀 Metering valve |
| 04/03/2002 | CN1343129A Sustained release salts of pharmaceutically active peptides are their production |